Ainos, Inc. (AIMD)
NASDAQ: AIMD · Real-Time Price · USD
0.430
+0.004 (0.94%)
Nov 20, 2024, 4:00 PM EST - Market closed
Ainos Employees
Ainos had 46 employees as of December 31, 2023. The number of employees increased by 3 or 6.98% compared to the previous year.
Employees
46
Change (1Y)
3
Growth (1Y)
6.98%
Revenue / Employee
$883
Profits / Employee
-$350,732
Market Cap
5.95M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Cutera | 430 |
| Biora Therapeutics | 58 |
| Sharps Technology | 57 |
| Intelligent Bio Solutions | 50 |
| Viracta Therapeutics | 40 |
| TransCode Therapeutics | 10 |
| Alzamend Neuro | 7 |
| Mangoceuticals | 3 |
AIMD News
- 7 days ago - Water Tower Research Highlights IRB Approval for the Ainos VELDONA Clinical Sjogren's Trial Alongside 3Q24 Earnings and Developments - Accesswire
- 9 days ago - Ainos Announces IRB Approval for Sjögren's Syndrome Clinical Study at Shuang Ho Hospital, Affiliated with Taipei Medical University, and Plans to Initiate New Phase of Treatment Evaluation in Q1 2025 - Accesswire
- 12 days ago - Ainos Takes Decisive Action to Protect Stockholder Interests and Combat Potential Illegal Trading Activities - Accesswire
- 14 days ago - Ainos Reports Third Quarter 2024 Financial Results - Accesswire
- 23 days ago - Ainos Expands Patent Portfolio With Strategic Shareholder's Cutting-Edge Technology Assets - Accesswire
- 27 days ago - Ainos Highlights VELDONA Clinical Advancements and Market Potential in Water Tower Research Spotlight Podcast - Accesswire
- 6 weeks ago - Ainos Advances Healthcare and Industrial Innovations with AI Nose and VELDONA Technologies - Accesswire
- 2 months ago - Ainos, Inc. Receives IRB Approval From National Taiwan University Hospital for HIV-Oral Warts Clinical Trial, Highlighting Value of FDA-Designated Orphan Drug VELDONA - Accesswire